

AGL Antibody (Center)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP2402a

Product Information

Application WB, IF, E **Primary Accession** P35573 Reactivity Human Host Rabbit Clonality Polyclonal Isotype Rabbit IgG **Calculated MW** 174764 **Antigen Region** 357-387

Additional Information

Gene ID 178

Other Names Glycogen debranching enzyme, Glycogen debrancher,

4-alpha-glucanotransferase, Oligo-1, 4-1, 4-glucantransferase, Amylo-alpha-1, 6-glucosidase, Amylo-1, 6-glucosidase, Dextrin 6-alpha-D-glucosidase, AGL,

GDE

Target/Specificity This AGL antibody is generated from rabbits immunized with a KLH

conjugated synthetic peptide between 357-387 amino acids from the Central

region of human AGL.

Dilution WB~~1:1000 IF~~1:10~50 E~~Use at an assay dependent concentration.

Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide.

This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation

followed by dialysis against PBS.

Storage Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store

at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions AGL Antibody (Center) is for research use only and not for use in diagnostic or

therapeutic procedures.

Protein Information

Name AGL

Synonyms GDE

Function Multifunctional enzyme acting as 1,4-alpha-D-glucan:1,4- alpha-D-glucan

4-alpha-D-glycosyltransferase and amylo-1,6-glucosidase in glycogen

degradation.

Cellular Location Cytoplasm. Note=Under glycogenolytic conditions localizes to the nucleus

Tissue Location Liver, kidney and lymphoblastoid cells express predominantly isoform 1;

whereas muscle and heart express not only isoform 1, but also

muscle-specific isoform mRNAs (isoforms 2, 3 and 4). Isoforms 5 and 6 are

present in both liver and muscle


Background

AGL is a glycogen debrancher enzyme which is involved in glycogen degradation. This enzyme has two independent catalytic activities which occur at different sites on the protein: a 4-alpha-glucotransferase activity and a amylo-1,6-glucosidase activity. Mutations in the AGL gene are associated with glycogen storage disease although a wide range of enzymatic and clinical variability occurs which may be due to tissue-specific alternative splicing.


References

Horinishi, A., et al., J. Hum. Genet. 47(2):55-59 (2002). Bao, Y., et al., Genomics 38(2):155-165 (1996). Yang, B.Z., et al., J. Biol. Chem. 267(13):9294-9299 (1992). Yang-Feng, T.L., et al., Genomics 13(4):931-934 (1992). Bao, Y., et al., Gene 197 (1-2), 389-398 (1997).

Images



Western blot analysis of hAGL-C371 (Cat. #AP2402a) in K562 cell line lysates (35ug/lane). AGL (arrow) was detected using the purified Pab.



Confocal immunofluorescent analysis of AGL Antibody (Center)(Cat#AP2402a) with HepG2 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green). DAPI was used to stain the cell nuclear (blue).

Citations

- Loss of glycogen debranching enzyme AGL drives bladder tumor growth via induction of hyaluronic acid synthesis.
- Muscle glycogen remodeling and glycogen phosphate metabolism following exhaustive exercise of wild type and laforin knockout mice.
- Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
- Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis.
- Abnormal metabolism of glycogen phosphate as a cause for Lafora disease.
- A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori\'s disease.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.